Tesevatinib

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Kidney, Autosomal Dominant

Conditions

Polycystic Kidney, Autosomal Dominant

Trial Timeline

Oct 11, 2012 → Feb 8, 2019

NCT ID

NCT01559363

About Tesevatinib

Tesevatinib is a phase 1/2 stage product being developed by Sanofi for Polycystic Kidney, Autosomal Dominant. The current trial status is completed. This product is registered under clinical trial identifier NCT01559363. Target conditions include Polycystic Kidney, Autosomal Dominant.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01559363	Phase 1/2	Completed	Oct 11, 2012	Feb 8, 2019	Polycystic Kidney, Autosomal Dominant

Competing Products

20 competing products in Polycystic Kidney, Autosomal Dominant

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	44
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	52
Elagolix + Placebo	AbbVie	Phase 2	52
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	77
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	33
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	52
IVF Antagonist Protocol	Merck	Pre-clinical	23
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	85
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	77
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	77
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	77
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	23
Placebo + Everolimus	Novartis	Approved	85
LIK066 + Placebo	Novartis	Phase 2	52
Octreotide + Placebo	Novartis	Phase 2/3	65
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	77
Everolimus + Octreotide LAR	Novartis	Phase 2	52
Atorvastatin + Placebo	Pfizer	Pre-clinical	22
Rapamune	Pfizer	Phase 1/2	40

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved